Below are the most recent publications written about "Cyclopropanes" by people in Profiles.
-
Shan Y, DeSouza N, Littman N, Qiu Q, Nguyen K, Yu Y, Mohi G, Li S. A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of JAK2V617F-induced polycythemia vera. Haematologica. 2025 Nov 01; 110(11):2702-2713.
-
Rothman RL, Stewart TG, Mourad A, Boulware DR, McCarthy MW, Thicklin F, Garcia Del Sol IT, Garcia JL, Bramante CT, Shah NS, Singh U, Williamson JC, Rebolledo PA, Jagannathan P, Schwasinger-Schmidt T, Ginde AA, Castro M, Jayaweera D, Sulkowski M, Gentile N, McTigue K, Felker GM, DeLong A, Wilder R, Collins S, Dunsmore SE, Adam SJ, Hanna GJ, Shenkman E, Hernandez AF, Naggie S, Lindsell CJ. Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial. JAMA Netw Open. 2024 10 01; 7(10):e2439332.
-
Tawil R, Wagner KR, Hamel JI, Leung DG, Statland JM, Wang LH, Genge A, Sacconi S, Lochm?ller H, Reyes-Leiva D, Diaz-Manera J, Alonso-Perez J, Muelas N, Vilchez JJ, Pestronk A, Gibson S, Goyal NA, Hayward LJ, Johnson N, LoRusso S, Freimer M, Shieh PB, Subramony SH, van Engelen B, Kools J, Leinhard OD, Widholm P, Morabito C, Moxham CM, Cadavid D, Mellion ML, Odueyungbo A, Tracewell WG, Accorsi A, Ronco L, Gould RJ, Shoskes J, Rojas LA, Jiang JG. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2024 05; 23(5):477-486.
-
Connolly PJ, Quigg M, Davis EM. Improvement in non-24-h sleep-wake rhythm disorder in a sighted individual treated with a melatonin receptor agonist. Sleep Med. 2024 04; 116:41-42.
-
Nicolas SE, Bear MD, Kanaan AO, Coman OA, Dima L. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis. Am J Ther. 2023 Nov-Dec 01; 30(6):e535-e542.
-
Siegel EL, Olivera M, Roig EM, Perry M, Li AY, D'hers S, Elman NM, Rich SM. Spatial repellents transfluthrin and metofluthrin affect the behavior of Dermacentor variabilis, Amblyomma americanum, and Ixodes scapularis in an in vitro vertical climb assay. PLoS One. 2022; 17(11):e0269150.
-
Zephyr J, Nageswara Rao D, Vo SV, Henes M, Kosovrasti K, Matthew AN, Hedger AK, Timm J, Chan ET, Ali A, Kurt Yilmaz N, Schiffer CA. Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance. J Mol Biol. 2022 05 15; 434(9):167503.
-
Mellion ML, Ronco L, Berends CL, Pagan L, Brooks S, van Esdonk MJ, van Brummelen EMJ, Odueyungbo A, Thompson LA, Hage M, Badrising UA, Raines S, Tracewell WG, van Engelen B, Cadavid D, Groeneveld GJ. Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. Br J Clin Pharmacol. 2021 12; 87(12):4658-4669.
-
Britch SC, Kline DL, Linthicum KJ, Urban J, Dickstein E, Aldridge RL, Golden FV. Transfluthrin Spatial Repellent on US Military Camouflage Netting Reduces Tabanids in a Warm-Temperate Environment. J Am Mosq Control Assoc. 2020 09 01; 36(3):212-215.
-
Moore DC, Arnall JR, Thompson DL, Martin AL, Robinson J, Ndiaye A, Paul B, Atrash S, Bhutani M, Voorhees PM, Usmani SZ. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):e777-e781.